Leukocyte recruitment from the blood into injured tissues during inflammatory diseases is the result from sequential events involving chemokines binding to their GPC receptors as well as to their glycosaminoglycan (GAG) coreceptors. The induction and the crucial role of MCP-1/CCL2 in the course of diseases which feature monocyte-rich infiltrates have been validated in many animal models and several MCP-1/CCL2 as well as CCR2 antagonists have since been generated. However, despite some of them were shown to be efficacious in a number of animal models, many failed in clinical trials and therapeutically interfering with this chemokine's activity is not possible yet. We have therefore generated novel MCP-1/CCL2 mutants with increased GAG binding affinity and knocked-out CCR2 activity which were designed to interrupt the MCP-1/CCL2-related signalling cascade. We provide evidence that our lead mutant MCP-1(Y13AS21KQ23R) exhibits a four-fold higher affinity towards the natural MCP-1 GAG ligand heparan sulfate and that it shows a complete deficiency in activating CCR2 on THP-1 cells. Furthermore, a significantly longer residual time on GAG ligands was observed by surface plasmon resonance. Finally, we were able to show that MCP-1(Y13AS21KQ23R) had a mild ameliorating effect on experimental autoimmune uveitis and that a marginal effect on oral tolerance in the group co-fed with Met-MCP-1(Y13AS21KQ23R) plus immunogenic peptide PDSAg was observed. These results suggest that disrupting wild type chemokine-GAG interactions by a chemokine-based antagonist can result in anti-inflammatory activity which could have potential therapeutic implications.
Leukocyte recruitment from the blood into injured tissues during inflammatory diseases is the result from sequential events involving chemokines binding to their GPC receptors as well as to their glycosaminoglycan (GAG) coreceptors. The induction and the crucial role of MCP-1/CCL2 in the course of diseases which feature monocyte-rich infiltrates have been validated in many animal models and several MCP-1/CCL2 as well as CCR2 antagonists have since been generated. However, despite some of them were shown to be efficacious in a number of animal models, many failed in clinical trials and therapeutically interfering with this chemokine's activity is not possible yet. We have therefore generated novel MCP-1/CCL2 mutants with increased GAG binding affinity and knocked-out CCR2 activity which were designed to interrupt the MCP-1/CCL2-related signalling cascade. We provide evidence that our lead mutant MCP-1(Y13AS21KQ23R) exhibits a four-fold higher affinity towards the natural MCP-1 GAG ligand heparan sulfate and that it shows a complete deficiency in activating CCR2 on THP-1 cells. Furthermore, a significantly longer residual time on GAG ligands was observed by surface plasmon resonance. Finally, we were able to show that MCP-1(Y13AS21KQ23R) had a mild ameliorating effect on experimental autoimmune uveitis and that a marginal effect on oral tolerance in the group co-fed with Met-MCP-1(Y13AS21KQ23R) plus immunogenic peptide PDSAg was observed. These results suggest that disrupting wild type chemokine-GAG interactions by a chemokine-based antagonist can result in anti-inflammatory activity which could have potential therapeutic implications.
Chemokines are small secreted proteins which function as messengers by orchestrating activation and directional migration of specific subtypes of leukocytes from the blood stream into injured tissues (1) (2) (3) . They exert their specific functions through interactions with G protein-coupled receptors (GPCRs) on the one hand, and with cell-surface proteoglycans (PGs) on the other hand which we therefore call chemokine co-receptors to differentiate them from the "classical" chemokine GPC receptors. PGs are commonly defined as silent receptors although evidence accumulates which shows that PGs binding chemokines exhibit nonclassical downstream signalling in endothelial cells (Falsone et al., unpublished results). Within the CC family of chemokines, MCP-1/CCL2 specifically recruits and activates CCR2 positive cells. Thus MCP-1 is highly induced in a variety of diseases that feature monocyte-rich cellular infiltrates such as in atherosclerosis (4) (5) , congestive heart failure (6-7), rheumatoid arthritis (8) (9) (10) , inflammatory bowel disease (11) and uveitis (12) (13) (14) . Unlike many other chemokines, MCP-1/CCL2 binds exclusively to CCR2 and the importance of this chemokinereceptor pair in mouse models of inflammatory disesases, including multiple sclerosis, atherosclerosis and uveitis has been confirmed (12) (13) (14) (15) (16) (17) . It has, for example, been shown that knockout mice lacking MCP-1/CCL2 are unable to recruit monocytes and T-cells to inflammatory lesions (18) (19) (20) (21) . LDL-receptor/MCP-1-deficient and apoB-transgenic/MCP-1-deficient mice showed considerably less lipid deposition and macrophage accumulation throughout their aortas compared to the wtMCP-1 strains (22) (23) . Finally, CCR2 knockout mice were found to be resistant to experimental autoimmune encephalomyelitis (16) .
Many attempts to interfere with MCP-1/CCL2 activity have been made by applying several therapeutic strategies. Neutralizing mAb's against both MCP-1/CCL2 and CCR2 have been tested in vivo where they exhibited an ameliorating effect on mouse crescentic glomerulonephritis and on restenosis in nonhuman primates (24) (25) . Truncation or modification of the N-terminus yielded receptor antagonists of MCP-1 (9-76) which failed to reduce the severity of the spontaneous onset of arthritis in lpr mice (26), as well as to being efficacious in a mouse model of atherosclerosis (27) (28) . MCP-1/CCL2 oligomerization is known to be required for activity in vivo (29) , thus the abrogation of oligomerization has been investigated for its potential in antiinflammatory activity. For instance, the mutant form CCL2(P8A) has been engineered which is an obligate monomer and which was unable to recruit leukocytes into the peritoneal cavity and into lungs of OVA-sensitized mice (30) . Glycosaminoglycan (GAG) binding of chemokines has been shown to be essential to promote cell migration in vivo (29) . Heparin and heparin derivatives exhibited mild antiinflammatory effects in animal models as well as in humans (32) . Although the true mechanism of action of heparin in these studies is not known, the inhibition of the interaction between chemokines and cell surface GAGs has been suggested as a viable therapeutic strategy. GAGbinding deficient variants of MCP-1 (29, 31) and RANTES (29) have been generated in order to obtain mutant chemokines which would compete with their wild type counterparts on leukocyte GPCRs while their impaired GAG binding would result in anti-inflammatory activity. The antagonistic activity of these mutants in vivo has been related also to their oligomerization behaviour which differed from the wild type chemokines (33) (34) . These so-called GAG knock-out mutants represent the mirror image of the GAG knock-in mutants presented in this manuscript (see below), by which we aim to antagonise at the GAG binding site while impairing the chemokine's GPCR activity.
Despite several chemokines and chemokine receptors have been targeted successfully in animal models of immunemediated diseases, species specificity of small antagonists and neutralizing mAb's complicate the use of these compounds in animal models. Hence the development and the assessment of efficacy of some antagonists may be delayed. Additionally, the low oral bioavailability of some of the compounds may also prevent broad clinical applications. Up to now, the data on the effects of chemokine blockade in patients are still limited and dissatisfying. A trial with an anti-CCL2 mAb in patients with rheumatoid arthritis did result neither in clinical nor in immunohistological improvement and administration of the highest dose may have been associated with worsening of arthritis (35) . The effect of chemokines (or chemokine receptor) blockade seems, furthermore, to be dependent on the time of inhibitor administration. Administration of anti-CCR2 mAb or small molecule antagonist of MCP-1 before CIA or AIA onset resulted in disease amelioration, whereas CCR2 blockade after disease onset aggravated the clinical and histological scores of experimental arthritis (36) (37) (38) . Similarly, treatment with MCP-1(9-76) (39), which inhibits MCP-1 binding to CCR2, prevented the CFA-mediated exacerbation of the spontaneous development of arthritis in MRLlpr mice, but was less efficacious if administered after disease onset (26, 37).
We have generated new MCP-1/CCL2 mutants by site-directed mutagenesis aiming to modulate the protein's function in vitro and in vivo. Assuming that the chemokine-GAG interaction is indispensable for chemokine activity in vivo (29), we identified solventexposed residues that, when mutated into basic amino acids, increased the protein affinity to the MCP-1/CCL2-specific GAG ligands. We additionally mutated the position 13 into alanine which abolished signalling through CCR2. From all these dominant-negative mutants Met-MCP-1(Y13AS21KQ23R) showed the highest GAG binding affinity and complete knock-out of CCR2 signalling in vitro. In addition, we show here that it considerably reduced ocular monocyte tissue infiltration in a rat experimental autoimmune uveitis model (EAU). In a separate study we have recently shown that this mutant exhibits strong inhibitory activity also in a murine model of myocard infarction and restenosis (Zernecke et al., manuscript submitted). Although only few residues have been mutated, the results suggest that Met-MCP-1(Y13AS21KQ23R) acts as a protein-based GAG antagonist and that the mechanism for its inhibitory activity arises from the dual modifications, as we anticipated recently (40) .
Experimental procedures
Generation of Human MCP-1 Mutants for Expression in E. coli-All MCP-1 mutant constructs were generated in the context of MCP-1 M64I, referred to as WT*. WT* behaves identically to wild type in binding and activity assays. This alteration in the primary structure improves the purity and homogeneity of the mutants by eliminating the formation of species containing methionine-sulfoxide at position 64 (41) .
The gene for WT* MCP-1 was constructed by standard gene synthesis techniques with optimal codon usage for expression in E. coli and was cloned into a pCP116 expression vector (42 Cultures were grown in 3L Erlenmeyer flasks under shaking at 37°C in LB broth containing 150 μg/ml ampicillin to an OD 600 of 0.6. Protein expression was induced by addition of 0.5 mM isopropyl-β-D-thiogalactopyranoside. Cells were incubated with shaking for an additional 3-5 hours and harvested by centrifugation for 15 minutes at 6,500 x g. Each g wet cell pellet was resuspended in 4ml solution buffer, containing 10mM KH 2 PO 4 pH 7.5, 5mM MgCl 2 , and disrupted by sonication on ice. The lysate was then cleared by centrifugation for 30 minutes at 20,000 x g at 4°C. The inclusion body pellets were solubilised in 10ml solution buffer, containing 10mM KH 2 PO 4 pH 7.5 , guanidinium hydrochloride 6M, per g wet cell pellet under stirring for 1 hour at room temperature. After centrifugation for 30 minutes at 20,000 x g at 4°C the supernatant was dialyzed against 10mM KH 2 PO 4 pH 7.5 at 4°C. The precipitant was spun down and the solution was loaded on a SPSepharose high performance column (Amersham Bioscience). Mutants were eluted with a linear gradient from 10mM KH 2 PO 4 pH 7.5, 1mM EDTA to 10mM KH 2 PO 4 pH 7.5, 1mM EDTA, 1M NaCl over 60 minutes with a flow rate of 1ml/min; the MCP-1 mutants eluted at 0.6-0.8 M NaCl. Peak fractions were pooled and purified by reversed-phase HPLC on a C18 column. The mutants were eluted with a non linear gradient: from 10% to 40% acetonitrile (0,1% TFA) in 5 minutes, from 40% to 60% acetonitrile (0,1% TFA) in 20 minutes and from 60% to 90% acetonitrile (0,1% TFA) in 5 minutes with a flow rate of 0.8ml/min. Proteins eluted at 48 ± 5% acetonitrile and were refolded by loading them on a SP-Sepharose high performance column as described above. Peak fractions were dialyzed against PBS and concentrated to 1mg/ml. Purity and identity of the MCP-1 mutants were confirmed by silver-stained SDS-PAGE and nano-HPLC ESI-MS/MS, respectively. The bacterial endotoxin content of the protein samples was determined by the Limulus Amoebocyte Lysate (LAL) test (BioWhittaker, Cambrex).
Fluorescence Spectroscopy-Steady-state fluorescence measurements were performed on a Perkin-Elmer (Beaconsfield, England) LS50B fluorometer as described previously (43), and analyzed using the program Origin (Microcal Inc., Northampton, MA). The temperature was maintained at 22°C during all experiments by coupling to an external water bath.
Isothermal Fluorescence Titration Experiments (IFT)-The emission spectra of 0,5 wtMCP-1/CCL2 and mutant solutions in PBS were recorded over the range of 310-390 nm upon excitation at 282 nm. The excitation and emission slit widths were set at 15 and 20 nm respectively and a 290 nm cut off filter was inserted into the emission path to avoid stray light. The spectra were recorded at a speed of 200 nm/min. The addition of GAG aliquots was followed by an equilibration period of 1 min before the next spectrum was recorded. After background subtraction, the spectra were integrated and the normalized mean changes in fluorescence intensity (-∆F/F 0 ) obtained from two independent experiments were averaged and plotted against the volume corrected concentration of the added ligand. The resulting binding isotherms were analyzed by non-linear regression to an equation describing a bimolecular association reaction as described elsewhere (44) .
Surface Plasmon Resonance AnalysisBinding of wtMCP-1/CCL2, Met-MCP-1(Y13AS21K) and Met-MCP-1(Y13AS21KQ23R) to unfractionated heparan sulfate was investigated on a BIAcore 3000 instrument (BIAcore AB, Uppsala, Sweden). The immobilisation of the biotinylated GAG onto a streptavidin coated CM4 sensor chip was performed according to an established protocol, described recently (45) . The actual binding interactions were recorded at 25°C in PBS pH 7.4 containing 0.01% (v/v) P20 surfactant (BIAcore AB). 4 min injections of different protein concentrations at a flow rate of 30µl/min were followed by 10 min dissociation periods in buffer and a pulse of 1M sodium chloride for complete regeneration. The maximum response signals of protein binding to the GAG surface, corresponding to the plateaus of the respective sensorgrams, were used for Scatchard plot analysis and the calculation of equilibrium dissociation constants (K d values). The experiments were all carried out at a protein concentration of 600nM, which has been chosen on the basis of a series of ligand binding experiments performed at several protein concentrations ranging from 50nM up to 1,2μM. Using the BIAevaluation software, koffs were calculated by separately fitting the dissociation phases according to the 1:1 Langmuir interaction model.
Chemokine displacement assay-wT MCP-1 (PeproTech) was labeled with fluorescein isothiocyanate (Sigma). For this purpose, 500µg protein (in PBS) and a 4-fold molar excess of FITC were mixed and incubated at room temperature under moderate shaking (200 rpm) for 2 hours. Free FITC was removed by centrifugation through ZEBA desalting columns (Pierce), and final protein concentration was determined photometrically. Streptavidin coated 96 well plates (Nunc) were washed with NaPi buffer (10 mM Na-phosphate buffer, mono-and dibasic, 50 mM NaCl, pH 7.0) and coated with biotinylated HS. This step was performed at room temperature under moderate shakin ( incubation time = 1 hour). The plates were washed three times with NaPi buffer. In each well 100µL fluorescently labeled wT MCP-1 was placed and incubated for 30 min under moderate shaking. The plates were washed again and finally 100µL of the respective competitor at a concentration ranging from 1nM to 50µM were added to the wells in a interval of 20 sec to maintain an incubation time of 5 min in every well. After incubation, 95µL were taken off, applied to untreated black 96 well plates (Greiner) and fluorescence (excitation 485nm, emission 535nm, integration time 1 sec) was measured with a Beckman Coulter DTX800 instrument.
Cells-The THP-1 monocytic cell line was purchased from the European collection of cell cultures and grown in RPMI 1640 medium (Sigma) containing 10% fetal calf serum, 2mM glutamine, 100 units/ml penicillin and 100 units/ml streptomycin, at 37°C and 5% CO 2 . Primary monocytes were obtained from whole blood by collection with vacuette (Greiner) containing K 2 EDTA diluted (1:1 v/v) with HBSS(-) (PAA) followed by centrifugation through Ficoll Paque Premium (GE Healthcare). The interface between plasma and Ficoll (containing mononuclear cells) was taken carefully and washed twice with HBSS(-) to remove platelets. Then the pellet was resuspended in HBSS(+) to a concentration of 2 x 10 6 cells/mL (calculated to quota of monocytes). The cells were used immediately after preparation.
Chemotaxis Assay-The ability of wtMCP-1/CCL2 and mutants to mediate the migration of freshly prepared human bloodderived monocytes was investigated using a 48-well Boyden chamber system (Neuroprobe) equipped with 5μm polycarbonate PVP free membranes. Wild type MCP-1/CCL2 and MCP-1 mutant dilutions ranging from 5nM to 20nM in PBS were placed in the lower wells of the chamber in triplicates, including wells with buffer alone. 50μl of mononuclear cell suspension in HBSS(+) at 2 x 10 6 cells/ml was placed in the upper wells. After 1 hour incubation period at 37°C and 5% CO 2 the upper surface of the membrane was washed with PBS. The migrated cells were fixed in methanol and stained with Hemacolor® (Merck). The migrated cells of five 400 x magnifications per well were counted and the mean of three independently conducted experiments was background corrected and plotted against the chemokine concentration.
Calcium Mobilization Assay-THP-1 cells were loaded with Fura in Krebs Ringer Buffer containing 1mg/ml BSA and 3μM Fura-2-acetoxymethylester for 30 minutes at 37°C, washed with PBS and kept on ice. Just before use the cells were resuspended at 2 x 10 6 cells/ml in Krebs Ringer buffer at 37°C and equilibrated for 10 minutes. The fluorescence emission at 495nm was monitored upon excitation at 340nm at 37°C under low stirring. Calcium mobilization was induced by addition of 20nM chemokine. The minimum fluorescence was determined after addition of 1,8mM EGTA, 14mM Tris HCl and 0,1% Triton X-100, and the maximum fluorescence after subsequent addition of 10mM HCl and 5mM CaCl 2 . Rats were subcutanously immunized with 15 µg peptide in complete Freund's adjuvant (CFA) as described (46) . MCP-1 variant Met-MCP-1(Y13AS21KQ23R) (100 µg /rat) was injected i. p. daily, from immunization until indicated. Time course of disease was determined by daily examination with an ophthalmoscope. Uveitis was graded clinically as described by de Smet et al. (53) . Histological grading of cryosections from rat eyes was performed as previously published (46) .
Induction of Experimental Autoimmune Uveitis (EAU)-
Induction of Oral Tolerance-Animals were fed by gavage with either PBS, PDSAg (200 µg), Met-MCP-1(Y13AS21KQ23R) (100 µg), or with PDSAg and Met-MCP-1(Y13AS21KQ23R). PDSAg was given orally three times every other day, while Met-MCP-1(Y13AS21KQ23R) was fed 7 times, daily until the day before immunization. Animals were immunized with 15 µg PDSAg/CFA 3 days after the last peptide application.
Statistical methods-Mean standard deviation and statistical significance were calculated using Origin (Microcal Inc., Northampton, MA). For statistical analysis, a one-way ANOVA followed by a Dunnett post test was used with a 95% confidence interval. *** = p<0.001 (extremely significant), ** = p<0.01 (very significant) and * = p<0.05 (significant).
RESULTS

Engineering of MCP-1/CCL2 mutants -
Four novel MCP-1/CCL2 mutants have been rationally engineered to identify an effective, novel strategy to antagonize GAG-related inflammatory responses. The GAG binding domain of MCP-1/CCL2 was recently mapped and was found to consist of arginine 18 and 24, lysine 19, 49 and 58 and histidine 66 as key residues for the chemokine-GAG interactions (31) . A tetrameric structure has been proposed as the fundamental quaternary structure of MCP-1/CCL2 in the heparin-bound state. The GAG binding hotspots create a large positively charged surface that encircle the tetramer and, in principle, can interact with an extended GAG chain (31) . The receptor binding and activation site has been described and shows tyrosine 13 at the N-terminus as key signalling residue (31, 41, (48) (49) . The strategy applied here aimed at increasing the GAG binding affinity whilst knocking-out receptor activation. Our approach takes advantage of the significant overlap between the receptor and the GAG binding domains of MCP-1, thereby avoiding deletions or excessive mutations which could lead to a total structural collapse and to higher immunogenicity. To increase GAG binding affinity, residues with solvent exposed areas > 30% and proximal to the mapped GAG binding site have been carefully selected and replaced with basic amino acids (see Fig. 1 ). The N-terminal methionine residue, retained by the protein due to E.coli expression, was not cleaved after bacterial expression since it did not compromise the binding affinity of the proteins to HS, as demonstrated by isothermal titration experiments (Piccinini A. M. et al., manuscript submitted) but rather increased the apparent binding affinity to heparin as has been shown elsewhere (31) . Moreover the N-terminal methionine was found to reduce the binding affinity of MCP-1/CCL2 for CCR2 on THP-1 cells (49) and the chemotactic potency of the chemokine, which is approximately 300-fold lower than for the wild type (48) . In addition, in order to fully knock out receptor activation of MCP-1, we have mutated the tyrosine residue at position 13 to alanine.
Applying this strategy, Met-MCP-1,
and Met-MCP-1(Y13AS21KQ23RV47K) were cloned, expressed and purified as described in materials and methods. All MCP-1 mutants were >95% pure as confirmed by SDS-PAGE followed by silver stain (Figure 3) .
GAG binding characterization-Heparan sulphate (HS) together with chondroitin sulphate (CS) are the most frequently observed GAG molecules involved in physiological and pathological processes taking place on the cell surface and in the extracellular matrix (50) . Moreover, HS exhibits a much higher structural heterogeneity compared to the well-known heparin and is thus expected to show higher sequence-related selectivity for specific protein ligands. Recently it has been shown that MCP-1/CCL2 binds to a heparin octasaccharide/11SO 3 and heparin octasaccharide/12SO 3 (51). However, the precise structure of the natural GAG is not yet known although the above mentioned positions of sulfation seem to be prerequisites for binding. We have used commercially-available unfractionated HS to increase the probability of having the MCP-1-specific GAG sequence contained in our ligand preparation. Taking advantage of the tryptophan residue at position 59 of MCP-1/CCL2, an intrinsic fluorophore which is sensitive to conformational changes, the MCP-1-GAG interactions have been quantified by isothermal fluorescence titrations (IFTs). Changes of the (normalized) tryptophan fluorescence emission (∆F/F 0 ) upon HS addition were plotted against increasing ligand concentrations and, from the resulting binding isotherms, the apparent dissociation constants (K d values) were calculated based on a bi-molecular interaction. The K d values found by these experiments are summarized in Figure 2a . Replacement of Ser21 and Gln23 by lysine and/or arginine residues, respectively, successfully increased the apparent affinity to HS, whereas the additional substitution of Val47 by lysine did not further enhance the affinity. In order to investigate the general GAG specificity of our MCP-1/CCL2 mutants, we performed, in addition to the HS binding experiments, IFT experiments with dermatan sulfate (DS) as ligand. DS (or CS-B) belongs to the chondroitin sulfate GAG family in which the GlcA residues are epimerised into IdoA. Interestingly, the affinities detected for all MCP-1/CCL2 proteins were in general lower for DS compared to HS (see Fig. 2c ), just the Met-MCP-1(Y13AS21KV47K) mutant displayed similar affinities for both GAG ligands. The relatively highest affinity for both GAG ligands was found for the Met-MCP-1(Y13AS21KQ23R) mutant. Those mutants carrying basic amino acids only at positions 21 and 23 were further investigated by surface plasmon resonance (SPR) analysis with respect to their HS binding properties. Scatchard plots and SPR sensorgrams of Met-MCP-1(Y13AS21K) and Met-MCP-1(Y13AS21KQ23R) in comparison with wtMCP-1 are shown in Figures 3a and 3b . Both methods applied, IFT and SPR, identified Met-MCP-1(Y13AS21KQ23R) as the variant with highest HS affinity compared to the wild type chemokine (Fig. 2b and 3a,b) . In fact the K d value of Met-MCP-1(Y13AS21KQ23R) obtained by IFT and SPR analysis are extremely similar, 156nM and 152nM respectively. Our rational protein design approach thus led to an increased GAG binding affinity by a factor of five which was confirmed by two independent methods.
MCP-1/CCL2 displacement experiments -since the natural situation, in which our MCP-1/CCL2-based mutants will encounter their GAG ligand, will be a GAG chain occupied by the wild type chemokine, we performed chemokine displacement experiments using fluorescently labelled wild type MCP-1/CCL2 as protein pre-bound to HS and the MCP-1/CCL2 mutants as competitors (see Figure 4) . Calcium mobilization assay and chemotaxis assay-The knock-out of the GPCR domain and the consequent abrogation of downstream signalling via CCR2 has been verified by investigating the ability of the MCP-1/CCL2 variants to induce calcium mobilization from THP-1 cells and to recruit primary monocytic cells in a standard chemotaxis assay in comparison to wtMCP-1/CCL2 (primary monocytes could not be used in the calcium mobilisation assays because of the insufficient number of CCR2(+) cells derived from whole human blood). In the calcium mobilization assay, wtMCP-1/CCL2 showed the maximum response at a protein concentration of 20nM. Both mutants, Met-MCP-1(Y13AS21K) and Met-MCP-1(Y13AS21KQ23R), were used at the same concentration as the wild type and were not able to induce any calcium influx under these conditions (Fig. 5a) . Interestingly, Met-MCP-1(Y13AS21KV47K) and Met-MCP-1(Y13AS21KQ23RV47K) retained partially the ability to induce calcium mobilization (Fig. 5b) . Chemotaxis of freshly prepared, human bloodderived monocytes has been performed in a 48-well modified Boyden chamber and the strongest cell migration was induced by wtMCP-1 at a concentration of 20nM.
Met-MCP-1(Y13AS21K)
and Met-MCP-1(Y13AS21KQ23RV47K) showed the strongest reduction in chemotactic activity by 90% (Fig.  6) . Overall, a residual chemotactic activity of the MCP-1/CCL2 mutants in the range of 10% compared to the wild type chemokine was observed. The effect of our engineered mutants on wtMCP-1/CCL2-induced chemotaxis was investigated in order to estimate the potential of mutant binding to CCR2. In Fig. 7 we have shown the chemotaxis of human blood-derived monocytes by a constant concentration MCP-1/CCL2 (20 nM) in the presence of increasing concentrations of Met-MCP-1(Y13AS21KQ23R). Interestingly, the mutant inhibited monocyte chemotaxis significantly at all concentrations investigated here referring to a residual ability of the engineered protein to bind to CCR2. This has been independently confirmed in a radioligand CCR2 displacement assay (Zernecke et al., manuscript submitted). Due to the insufficient number of CCR2(+) cells derived from human blood, we were not able to study the inhibitory effect of Met-MCP-1(Y13AS21KQ23R) on MCP-1/CCL2-induced calcium mobilisation.
Effect of Met-MCP-1(Y13AS21KQ23R) on the induction of uveitis and oral tolerance-
Uveitis is an inflammatory autoimmune disease of the immune-privileged inner eye and one of the major causes of blindness in industrialized countries. Experimental autoimmune uveitis (EAU) in Lewis rats is mediated by CD4 + T cells with specificity for retinal antigens, which secrete cytokines and chemokines to recruit other leukocytes that constitute the inflammatory infiltrates in uveitis. Here T cell mediated inflammation of the inner eye has been induced by active immunization with a peptide of the retinal soluble antigen (PDSAg), which is also thought to be an autoantigen in the human disease (46) (47) . Inflammation and subsequent tissue damage are induced by autoreactive Th1 lymphocytes and propagated by recruited mononuclear cells including monocytes and macrophages. Particularly the chemokines MCP-1 and RANTES are thought to play a key role in the recruitment of effector cells in uveitis (12) (13) (14) .
Intraperitoneal injection of Met-MCP-1(Y13AS21KQ23R) from the day of immunization until the end of the experiment on day 22 had a mild ameliorating effect on PDSAg-induced uveitis (Fig. 8a, b) . In contrast, uveitis after immunization with peptide R14 was slightly deteriorated by treatment with Met-MCP-1(Y13AS21KQ23R) (data not shown). This observation is in concordance with our previous findings described for treatment with Met-RANTES (53) . The effect of Met-MCP-1(Y13AS21KQ23R) on oral tolerance was tested by daily oral application of the Met-MCP-1(Y13AS21KQ23R) variant during the period of oral tolerization with peptide PDSAg and prior to immunization with PDSAg-CFA (Fig. 9a, b) . We observed only a small effect on oral tolerance in the group fed with peptide and concomitantly with Met-MCP-1(Y13AS21KQ23R) compared to the group that had received only oral peptide (Fig. 9a) . Oral application of only Met-MCP-1(Y13AS21KQ23R) prior to immunization with PDSAg had a slightly ameliorating effect on the clinical course of the disease (representing the inflammation in the anterior chamber of the eye) (Fig. 9b) as observed for the injection of Met-MCP-1(Y13AS21KQ23R) after immunization with PDSAg (Fig. 8b) .
DISCUSSION
Inflammation is a complex response to injury and infection and represents a protective attempt by the organism to remove the harmful trigger and initiate the healing process. However, impaired regulation of inflammation can lead to extensive tissue damage, the pathological consequences of which include a variety of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, but also non-immune diseases such as atherosclerosis, ischaemic heart disease and cancer. Leukocytes are critically involved in the initiation and maintenance of inflammation by secreting cytokines and chemokines that enhance cell recruitment and activation. MCP-1/CCL2 is highly induced in many inflammatory conditions and is responsible for recruiting mononuclear cells to the site of injury by signalling through CCR2. In fact MCP-1/CCL2 and CCR2 null mice, which are unable to recruit monocytes and T cells to inflammatory lesions, show less lipid deposition and macrophage accumulation throughout their aortas in an atherosclerosis model (54), are resistant to experimental autoimmune encephalomyelitis (16) and are strongly protected against endotoxin-induced uveitis (13) .
Given the importance of MCP-1/CCL2 in human disease, various therapeutic strategies have been developed which target the activity of this CC chemokine in vivo at several levels. Many attempts by several laboratories have been performed to antagonize the chemokine oligomerization ability as well as the chemokine-receptor and GAG co-receptor interactions. These approaches include an obligate MCP-1/CCL2 monomer (P8A-CCL2) with impaired oligomerization ability (30), neutralising anti CCL-2 and anti-CCR2 monoclonal antibodies (24) (25) , modified MCP-1/CCL2 receptor antagonists, low molecular weight inhibitors of CCR2 (26-28, 36-38) and GAG-binding deficient mutants (29, 31) . Nevertheless, clinical trials conducted so far with MCP-1/CCL2 antagonists have been unsuccessful due to limitations such as species specificity of small antagonists and neutralizing mAb, low oral bioavailability of some compounds and the time and intervention dependent effect of chemokines or chemokine receptors blockade (36) (37) (38) .
With this in mind and prompted by the unmet need for a treatment effective in acute and transient inflammatory responses as well as in chronic inflammatory diseases, we targeted the GAG-binding affinity of MCP-1/CCL2 and its receptor activation ability to rationally convert the pro-inflammatory chemokine MCP-1/CCL2 into a protein with anti-inflammatory activity. In this work, taking into account the previously mapped receptor activation and GAG-binding sites on MCP-1/CCL2, we retained the Nterminal methionine after recombinant protein synthesis in E. coli and we mutated the tyrosine 13 to alanine to impair receptor activation and signalling. More importantly, novel mutagenesis studies were performed to identify residues that, if replaced by the basic amino acids lysine and/or arginine significantly increased the GAGbinding affinity. The rationale behind this strategy was to create MCP-1/CCL2 antagonists that compete with endogenous MCP-1/CCL2 for GAG-binding whilst being unable to activate its cognate GPC receptor which is highly expressed on monocytes during inflammatory conditions.
The domain structure of MCP-1/CCL2 is characterized by a partial overlap between the receptor activation site and the GAG-binding domain, which means that modifications of one site has mutual effects on the other. Four mutants have therefore been generated which have in common (a) a methionine residue at the N-terminus that has previously been shown to reduce the MCP-1/CCL2 chemotactic potency (48) and to increase the apparent GAG-binding affinity (31) , and (b) an alanine residue at position 13 to further impair receptor activation. Positions 21, 23 and 47 showed solvent exposed areas above 30% and were found to be located in close proximity to the mapped GAG binding site. These sites have been mutated either individually or in combination to lysine or arginine. The mutations S21K and Q23R, individually as well as in combination, increased the GAG-binding affinity significantly and contributed positively to abrogate receptor activation. A relatively similar but absolutely different affinity pattern for the mutants was found when the two major GAG ligands, HS and CS were compared (see Fig. 2 ), revealing CS as low affinity ligand of MCP-1/CCL2. In fluorescence-based MCP-1/CCL2 displacement experiments, only the mutant Met-MCP-1 (Y13AS21KQ23RV47K) showed almost no improvement in its IC50 value with respect to displacing wtMCP1/CCL2 from the HS ligand. Therefore, based on its overall molecular characteristics, the mutant Met-MCP-1(Y13AS21KQ23R) was identified as our lead compound based on its strongly impaired GPC receptor activity, its 87% disabled directional migration potency towards primary monocyte cells in the Boyden chamber assay, its completely knocked-out intracellular calcium mobilization activity, as well as its highest GAG-binding affinity. Isothermal fluorescence titrations and surface plasmon resonance experiments performed with the natural HS ligand gave for this mutant K d values of 156 and 152 nM, respectively.
The potential antagonistic activity of Met-MCP-1(Y13AS21KQ23R) has been proven in a rat model of experimental autoimmune uveitis (EAU). The mutant, administered from the time point of immunization during the entire course of the disease, decreased significantly the disease score in comparison to the animals treated only with PBS (see Fig. 8a,b) thus protecting the animals from the development of severe inner eye inflammation. Overall the animals treated with Met-MCP-1(Y13AS21KQ23R) showed a milder and delayed inflammatory response than PBS-treated animals during the 22 days kinetic of disease.
In summary, we propose here a novel strategy to antagonize MCP-1/CCL2-mediated inflammatory response characterized by an excessive monocyte infiltration. Competition with wtMCP-1 for the cell-surface-GAGs is proposed to be the mechanism of action of Met-MCP-1(Y13AS21KQ23R).
Assuming an upregulation of GAG co-receptors only at sites of inflammation and a selective interaction between MCP-1/CCL2 and its cognate GAG ligand, our approach might have significant advantages over therapeutic strategies applied so far. 
